| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | 8-Hydroxy Guanine, 8-OH-dG, 8OHG, 80G, 8-hydroxyguanine, 8-hydroxy-2'-deoxyguanosine, 8-hydroxyguanosine, 8 OHG, 8-OHG, 8OHdG |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | 8-hydroxy-guanosine-BSA and –casein conjugates |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
DNA and RNA damage are critical molecular events that contribute to the onset and progression of neurodegenerative diseases. These lesions arise from both endogenous metabolic processes and environmental stressors, including oxidative stress, inflammation, and exposure to neurotoxins. In neurons—cells with limited regenerative capacity—such damage can have profound and lasting effects.
Reactive oxygen and nitrogen species (RONS), such as hydroxyl radicals and peroxynitrite, induce oxidative modifications to nucleic acids. Key biomarkers of this damage include 8-hydroxyguanine (8-OHG), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and 8-hydroxyguanosine (8-OHG), which are associated with mutagenic base transversions and impaired transcriptional fidelity. These lesions disrupt gene expression, mitochondrial function, and synaptic signaling—hallmarks of neurodegenerative pathology.
In diseases such as Alzheimer’s, Parkinson’s, and ALS, persistent DNA and RNA damage activates neuroinflammatory pathways and accelerates neuronal loss. Moreover, the failure of DNA repair mechanisms exacerbates genomic instability, further compromising neural integrity.
Understanding the molecular signatures of nucleic acid damage offers valuable insights into disease mechanisms and provides a foundation for developing diagnostic biomarkers and targeted therapies aimed at preserving genomic stability and neuronal function.
Cite this product varies by variant:
- SMC-155D — Size: 100 ug: DNA/RNA Damage Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D, RRID: AB_889490)
- SMC-155D-A390 — Size: 100 ug: DNA/RNA Damage Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-A390, RRID: AB_2698483)
- SMC-155D-A488 — Size: 100 ug: DNA/RNA Damage Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-A488, RRID: AB_2698484)
- SMC-155D-A594 — Size: 100 ug: DNA/RNA Damage Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-A594, RRID: AB_2698486)
- SMC-155D-APC — Size: 100 ug: DNA/RNA Damage Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-APC, RRID: AB_2698492)
- SMC-155D-BI — Size: 100 ug: DNA/RNA Damage Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-BI, RRID: AB_2698493)
- SMC-155D-FITC — Size: 100 ug: DNA/RNA Damage Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-FITC, RRID: AB_2698494)
- SMC-155D-HRP — Size: 100 ug: DNA/RNA Damage Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-HRP, RRID: AB_2698495)
- SMC-155D-PCP — Size: 100 ug: DNA/RNA Damage Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-PCP, RRID: AB_2698497)
- SMC-155D-RPE — Size: 100 ug: DNA/RNA Damage Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155D-RPE, RRID: AB_2698498)
- SMC-155S — Size: 12 ug: DNA/RNA Damage Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-155S, RRID: AB_889490)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Pilger A. and Rudiger H.W. (2006) Int Arch Occup Environ Health. 80(1): 1-15.
3. Malins D.C. and Haimanot R. (1991) Cancer Res. 51(19): 5430-5432.
4. Kvam E. and Tyrrell R.M. (1997) Carcinogenesis 18(11): 2281-2283.
5. Kowluru R.A., Atasi L., and Ho Y.S. (2006) Invest Ophthalmol Vis Sci 47(4): 1594-9.
6. Bowers R. et al. (2004) Am J Respir Crit Care Med. 169(6): 764-9.
7. Cui J., Holmes E.H., Greene T.G., and Liu P.K. (2000) Faseb J. 14(7): 955-67.